|
|
||||||||
AJP - Endocrinology and Metabolism, Vol 258, Issue 1 E228-E233, Copyright © 1990 by American Physiological Society
ARTICLES |
W. F. Schwenk, P. C. Butler, M. W. Haymond and R. A. Rizza
Department of Medicine and Pediatrics, Mayo Foundation, Rochester, Minnesota 55905.
We have recently reported that during infusion of commercially available [6-3H]glucose, a radioactive nonglucose contaminant may accumulate in plasma causing errors in the measurement of glucose turnover. To determine whether purification of this tracer by HPLC (high-performance liquid chromatography) before infusion would eliminate the contaminant in plasma and remove the underestimation of glucose turnover reported during hyperinsulinemia, four normal subjects each underwent two 5-h euglycemic clamps during infusion of insulin (1 mU.kg-1.min-1). Glucose turnover was measured with either commercially available [6-3H]glucose or with HPLC-purified [6-3H]glucose. HPLC analysis of samples from the clamps done with commercially available [6-3H]glucose showed that 9.7% of the infused tracer and 26% of the "plasma glucose 3H radioactivity" were contaminants. In contrast, no contaminant was observed in the plasma during infusion of HPLC-purified [6-3H]glucose. During the last hour of the clamp, mean glucose turnover using commercially available [6-3H]glucose was less (P less than 0.01) than the mean glucose infusion rate (7.6 +/- 0.3 vs. 10.5 +/- 0.3 mg.kg-1.min-1) yielding apparent "negative" (P less than 0.001) hepatic glucose release. In contrast, when HPLC-purified [6-3H]glucose was employed, glucose turnover equaled the glucose infusion rate (10.4 +/- 0.9 vs. 10.2 +/- 0.9 mg.kg-1.min-1) and hepatic glucose release was no longer negative. We conclude that removal of a tritiated nonglucose contaminant in [6-3H]glucose by HPLC yields correct estimations of glucose turnover at steady state.
This article has been cited by other articles:
![]() |
A. Carpentier, B. W. Patterson, K. D. Uffelman, A. Giacca, M. Vranic, M. S. Cattral, and G. F. Lewis The Effect of Systemic Versus Portal Insulin Delivery in Pancreas Transplantation on Insulin Action and VLDL Metabolism Diabetes, June 1, 2001; 50(6): 1402 - 1413. [Abstract] [Full Text] |
||||
![]() |
G. F. Lewis, M. Vranic, and A. Giacca Role of free fatty acids and glucagon in the peripheral effect of insulin on glucose production in humans Am J Physiol Endocrinol Metab, July 1, 1998; 275(1): E177 - E186. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. McCall, S. R. Wiesenthal, Z. Q. Shi, K. Polonsky, and A. Giacca Insulin acutely suppresses glucose production by both peripheral and hepatic effects in normal dogs Am J Physiol Endocrinol Metab, February 1, 1998; 274(2): E346 - E356. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |